Contrast enhancement in magnetic resonance imaging in children research hub

(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)

This study looks at a new contrast dye called gadoquatrane in children having MRI scans. We want to see how the body handles the dye and if it's safe. This helps us understand if it's a good option for children of all ages needing these special scans.